ABALLI JOHN 4

What Happened John Aballi, President & CEO and a director of Exagen, received equity awards on March 12, 2026: 150,000 restricted stock units (RSUs) reported at $0 acquisition cost, and a 100,000-share stock option reported at $3.16 per share (reported value $316,000). These were grants/awards as part of compensation — not open-market purchases or sales.

Key Details

• Transaction date: March 12, 2026; Form 4 filed March 16, 2026 (filed within the two-business-day reporting window).
• RSUs: 150,000 units; each unit converts to one share upon vesting; reported acquisition value $0.
• Option grant: 100,000 underlying shares, exercise price $3.16, reported aggregate $316,000; the option is exercisable as it vests.
• Vesting (RSUs): 25% vests on each of the 1st, 2nd, 3rd and 4th anniversaries of February 21, 2026; subject to continued service. May fully vest upon qualifying termination in connection with a change in control.
• Vesting (Option): 25% vests on February 21, 2027, then 1/48th of the total shares vest at the end of each calendar month thereafter; also may fully vest upon qualifying termination in connection with a change in control.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.

Context These awards are typical executive compensation grants tied to continued service and performance/time-based vesting. They are not immediate stock purchases or sales and therefore do not directly signal the insider buying or selling shares in the open market. The option will only convert to shares if exercised after vesting (and would require payment of the strike price).